TY - JOUR
T1 - Inhibitory receptors on eosinophils
T2 - A direct hit to a possible Achilles heel?
AU - Munitz, Ariel
AU - Levi-Schaffer, Francesca
N1 - Funding Information:
Disclosure of potential conflict of interest: F. Levi-Schaffer has received grant support from Yissum, Israeli Ministry of Industry and Commerce, The Aimwell Charitable Trust UK, and The Israel Science Foundation. A. Munitz has declared that he has no conflict of interest.
Funding Information:
Supported in part by grants from Yissum, the Israeli Ministry of Industry and Commerce, the Aimwell Charitable Trust UK, and the Israel Science Foundation (Grant 213/05).
PY - 2007/6
Y1 - 2007/6
N2 - Since their discovery, much data have been accumulated on eosinophil differentiation, morphology, trafficking, and anatomical location(s) in health and disease. Although "classic" activation pathways (such as cytokines, chemokines, proinflammatory components, and adhesion molecules) regulating eosinophil activation have been widely explored, the presence of other activation molecules that might be disease specific is limited. Furthermore, the expression and function of inhibitory receptors on eosinophils have received scant attention. The need to identify new pathways that regulate eosinophil activation is a crucial goal as it can expand our knowledge on this peculiar cell and provide insights into important queries regarding the physiologic function of eosinophils. Over the past several years, it has become increasingly apparent that eosinophils express several receptors belonging to the immunoglobulin superfamily. In this review, we summarize the current knowledge on the expression and function of new pathways that govern eosinophil activation. In addition, we will propose some hypotheses regarding the ability to use these pathways as a future therapeutic approach. In conclusion, we assume that targeting inhibitory receptors on eosinophils may provide opportunities for immunoregulatory therapy in the near future.
AB - Since their discovery, much data have been accumulated on eosinophil differentiation, morphology, trafficking, and anatomical location(s) in health and disease. Although "classic" activation pathways (such as cytokines, chemokines, proinflammatory components, and adhesion molecules) regulating eosinophil activation have been widely explored, the presence of other activation molecules that might be disease specific is limited. Furthermore, the expression and function of inhibitory receptors on eosinophils have received scant attention. The need to identify new pathways that regulate eosinophil activation is a crucial goal as it can expand our knowledge on this peculiar cell and provide insights into important queries regarding the physiologic function of eosinophils. Over the past several years, it has become increasingly apparent that eosinophils express several receptors belonging to the immunoglobulin superfamily. In this review, we summarize the current knowledge on the expression and function of new pathways that govern eosinophil activation. In addition, we will propose some hypotheses regarding the ability to use these pathways as a future therapeutic approach. In conclusion, we assume that targeting inhibitory receptors on eosinophils may provide opportunities for immunoregulatory therapy in the near future.
KW - Eosinophil
KW - IRp60/CD300a
KW - ITIM
KW - inhibitory receptors
UR - http://www.scopus.com/inward/record.url?scp=34249798165&partnerID=8YFLogxK
U2 - 10.1016/j.jaci.2007.01.031
DO - 10.1016/j.jaci.2007.01.031
M3 - ???researchoutput.researchoutputtypes.contributiontojournal.systematicreview???
AN - SCOPUS:34249798165
SN - 0091-6749
VL - 119
SP - 1382
EP - 1387
JO - Journal of Allergy and Clinical Immunology
JF - Journal of Allergy and Clinical Immunology
IS - 6
ER -